NCT01265160Unknown不适用
Jiangzhuo Prescription ，Fenofibrate and Placebo in the Treatment of Hyperlipidemia (Syndrome of Phlegm Obstruction)Clinical Study (JZF)
Guang'anmen Hospital of China Academy of Chinese Medical Sciences4 个研究点 分布在 1 个国家目标入组 240 人开始时间: 2010年11月最近更新:
适应症
试验速览
- 阶段
- 不适用
- 入组人数
- 240
- 试验地点
- 4
研究概览
简要总结
Jiangzhuo prescription ,fenofibrate and placebo in the treatment of hyperlipidemia(syndrome of phlegm obstruction), randomized, parallel-controlled, multi-center clinical study
详细描述
Charged by the five research centers in line with traditional Chinese medicine syndrome of phlegm obstruction 240 cases have hyperlipidemia, and overweight, as well as hypertension or diabetes were randomly divided into Chinese herbal compound Jiangzhuo prescription group and western medicine fenofibrate group and placebo group.The treatment groups were compared 12-week regulation of blood lipids and step-down, blood sugar effect.
研究设计
- 研究类型
- Observational
- 观察模型
- Case Control
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Consistent with diagnosed hyperlipidemia, TG≥2.26mmol/L and ≤7.0mmol/L.
- •Aged 18-65 years old. 3.BMI ≥ 24kg/m2, but <35 kg/m
- •Waist circumference ≥ 90cm (male) or waist circumference ≥ 80cm (women).
- •Comply with any of the following 3 :bloode pressure elevated levels of:SBP ≥130mmHg or DBP ≥85mmHg; fasting plasma glucose (FPG) increased: FPG ≥ 100mg/dl (5.6mmol / l ), or previously diagnosed type 2 diabetes or have received appropriate treatment.
排除标准
- •Has been used to control lipidsdrugs, but use the time for those below the 3 month.
- •2.Secondary dyslipidemia, such as nephrotic syndrome, hyperthyroidism, etc. 3.Taking thyroid medications and other drugs that affect lipid metabolism, such as high-dose thiazide diuretics, β-receptor blockers, corticosteroids.
- •4.Severe diseases of heart, lung, liver, kidney, brain, blood ,etc. 5.With the treatment of insulin, sulfonylureas, rosiglitazone or metformin. 6.3 months prior to the study of myocardial infarction or unstable angina confirmed.
- •7.Uncontrolled blood sugar or after controlling FPG>7.0mmol/L or 2hPG>11.1mmol/L 8.Uncontrolled blood pressure or after contraolling blood pressure>140/90mmHg 9.ALT≥80mmol/L 10.Pregnancy, for pregnancy or breast-feeding women 11.Allergis of fibrates or Chinese medicine 12.Mental illness 13.Cancer patients 14.History of gallbladder disease or cholelithiasis 15.With the treatment of Cyclosporine or coumarin anticoagulants 16.The patient with other clinical studies in the past 3 months 17.History of alcoholism and drug dependence
研究者
研究点 (4)
Loading locations...
相似试验
招募中
不适用
Safety Study of Fenofibrate During PregnancySevere Hypertriglyceridemia During PregnancyNCT05883865First People's Hospital of Hangzhou250
Unknown
不适用
Jiangzhuo Qinggan Prescription and Irbesartan in the Treatment of Essential Hypertension(Hepatogastric Damp-heat)Clinical StudyMetabolic SyndromeHypertensionNCT01082835Guang'anmen Hospital of China Academy of Chinese Medical Sciences240
终止
2 期
A Study to Assess the Role of Fenofibrate in Preventing Ischemic Cholangiopathy After Liver TransplantationLiver TransplantNCT05514119Mayo Clinic6
已完成
3 期
Study of Ezetimibe and Fenofibrate in Patients With Mixed Hyperlipidemia (0653-036)(COMPLETED)HypercholesterolemiaHypertriglyceridemiaNCT00092573Organon and Co576
已完成
1 期
A Multiple Oral Doses Study Of PF-06427878 In Healthy Adult SubjectsHealthy SubjectsNCT02391623Pfizer40